Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-1 humanized monoclonal antibody
- Development stage
- Phase 2
- Lead developer
- Anke Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-PD-1 humanized monoclonal antibody is a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Anhui Anke Biotechnology, it is designed to bind to PD-1 on the surface of T cells, thereby inhibiting its interaction with ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signaling that tumors use to evade the immune system, effectively restoring T-cell mediated anti-tumor activity. The drug is currently being evaluated in Phase I/II clinical trials in China for the treatment of various advanced malignant solid tumors and lymphomas.
- Other names
- recombinant anti-PD-1 humanized monoclonal antibody
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on anti-PD-1 humanized monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-1 humanized monoclonal antibody.